| scholarly article | Q13442814 |
| P356 | DOI | 10.4269/AJTMH.2011.09-0516 |
| P953 | full work available at URL | http://intl.ajtmh.org/cgi/content/abstract/84/2/12 |
| https://doi.org/10.4269/ajtmh.2011.09-0516 | ||
| https://europepmc.org/articles/PMC3032485 | ||
| https://europepmc.org/articles/PMC3032485?pdf=render | ||
| https://www.ajtmh.org/downloadpdf/journals/tpmd/84/2_Suppl/article-p12.pdf | ||
| P932 | PMC publication ID | 3032485 |
| P698 | PubMed publication ID | 21292873 |
| P5875 | ResearchGate publication ID | 49809356 |
| P50 | author | Ricardo Palacios | Q79321800 |
| Giampietro Corradin | Q80329128 | ||
| Sócrates Herrea | Q91487036 | ||
| P2093 | author name string | Mario Chen-Mok | |
| Oscar Ramírez | |||
| Myriam Arévalo-Herrera | |||
| Sócrates Herrera | |||
| Olga Lucía Fernández | |||
| Omaira Vera | |||
| William Cárdenas | |||
| P2860 | cites work | Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults | Q21144326 |
| Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age | Q24658073 | ||
| Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor | Q24798369 | ||
| Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites | Q28212476 | ||
| Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei | Q28259011 | ||
| Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants | Q28303270 | ||
| Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes | Q30039117 | ||
| Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein | Q33318466 | ||
| Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. | Q33350210 | ||
| Oxidative folding of synthetic polypeptides S-protected as tert-butylthio derivatives | Q33368125 | ||
| Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. | Q33394245 | ||
| The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion | Q33984183 | ||
| Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen | Q34194609 | ||
| The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites | Q34237481 | ||
| Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial | Q34359432 | ||
| Preclinical Vaccine Study of Plasmodium vivax Circumsporozoite Protein Derived-Synthetic Polypeptides Formulated in Montanide ISA 720 and Montanide ISA 51 Adjuvants | Q34546208 | ||
| Aotus monkeys: their great value for anti-malaria vaccines and drug testing | Q34999470 | ||
| Immunity to liver stage malaria: considerations for vaccine design. | Q35085513 | ||
| Recent advances in the discovery and delivery of vaccine adjuvants | Q35209997 | ||
| Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge | Q36313990 | ||
| CD4+ cytolytic T cell clone confers protection against murine malaria | Q36353821 | ||
| Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity | Q36728808 | ||
| New horizons in adjuvants for vaccine development | Q37342049 | ||
| Progress toward malaria preerythrocytic vaccines | Q37704174 | ||
| Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. | Q37800094 | ||
| Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research | Q43890930 | ||
| Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. | Q44144363 | ||
| Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals | Q44144656 | ||
| Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein | Q44166515 | ||
| Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites | Q44172051 | ||
| A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group | Q44174498 | ||
| Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity | Q44785944 | ||
| The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity | Q44888648 | ||
| A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant | Q46423309 | ||
| Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial | Q46623264 | ||
| Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys | Q46807703 | ||
| A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults | Q47835936 | ||
| Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. | Q47838628 | ||
| Prevalence and level of antibodies to the circumsporozoite proteins of human malaria parasites, including a variant of Plasmodium vivax, in the population of two epidemiologically distinct areas in the state of Acre, Brazil | Q47853005 | ||
| A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria | Q47885076 | ||
| Antibodies against circumsporozoite proteins of Plasmodium falciparum induced by natural infection | Q47886779 | ||
| Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria | Q47888641 | ||
| Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax | Q47892124 | ||
| Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria | Q47907194 | ||
| Malaria-specific antibody subclasses in immune individuals: a key source of information for vaccine design. | Q47919936 | ||
| Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma | Q47971371 | ||
| Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite | Q47989675 | ||
| Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein | Q47999989 | ||
| Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine | Q48019407 | ||
| Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit | Q48019429 | ||
| Antibody response to Plasmodium vivax antigens in Fy-negative individuals from the Colombian Pacific coast. | Q48019469 | ||
| Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine | Q48035774 | ||
| Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. | Q48037206 | ||
| The use of oil adjuvants in therapeutic vaccines | Q79847029 | ||
| P433 | issue | 2 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| Plasmodium vivax | Q311376 | ||
| P304 | page(s) | 12-20 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | American Journal of Tropical Medicine and Hygiene | Q15766943 |
| P1476 | title | Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51 | |
| Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51 | |||
| P478 | volume | 84 |
| Q35877857 | A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions |
| Q38913324 | A Model to Study the Impact of Polymorphism Driven Liver-Stage Immune Evasion by Malaria Parasites, to Help Design Effective Cross-Reactive Vaccines |
| Q30352329 | An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. |
| Q35970236 | Antibody Profiling in Naïve and Semi-immune Individuals Experimentally Challenged with Plasmodium vivax Sporozoites |
| Q34606478 | Antigenicity and immunogenicity of Plasmodium vivax merozoite surface protein-3. |
| Q38958930 | Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct |
| Q39108985 | Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein |
| Q35924716 | Approaching the target: the path towards an effective malaria vaccine |
| Q42260871 | Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques |
| Q38597276 | Development of vaccines for Plasmodium vivax malaria |
| Q34466125 | High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants |
| Q33798074 | Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. |
| Q34234390 | Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis |
| Q35947469 | Induction of Multifunctional Broadly Reactive T Cell Responses by a Plasmodium vivax Circumsporozoite Protein Recombinant Chimera |
| Q36680084 | Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops). |
| Q42234578 | Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein |
| Q35191980 | Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol |
| Q35712522 | Malaria eradication and elimination: views on how to translate a vision into reality |
| Q37727503 | Malaria vaccines: high-throughput tools for antigens discovery with potential for their development |
| Q91792244 | Peptide-based vaccine successfully induces protective immunity against canine visceral leishmaniasis |
| Q33800285 | Plasmodium vivax antigen discovery based on alpha-helical coiled coil protein motif |
| Q28539992 | Plasmodium vivax sporozoite challenge in malaria-naïve and semi-immune Colombian volunteers |
| Q27021891 | Platform for Plasmodium vivax vaccine discovery and development |
| Q24273364 | Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax |
| Q34546208 | Preclinical Vaccine Study of Plasmodium vivax Circumsporozoite Protein Derived-Synthetic Polypeptides Formulated in Montanide ISA 720 and Montanide ISA 51 Adjuvants |
| Q33969129 | Prospects for malaria elimination in non-Amazonian regions of Latin America |
| Q36394182 | Recent advances in recombinant protein-based malaria vaccines |
| Q28742239 | Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HTTM and Montanide ISA 51 in rhesus macaques |
| Q28084805 | Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review |
| Q36766857 | Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation |
| Q56341814 | Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors |
| Q38062029 | Vaccines against Plasmodium vivax: a research challenge. |
| Q37638131 | What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates? |
| Q47134819 | malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication |
Search more.